A Phase 1/2 interventional study of hUC-MSC-Exos Nasal Spray in Autism Spectrum Disorder (ASD and Prospective Study, sponsored by Dongfang People's Hospital. Recruiting at 1 site in China. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Dongfang People's Hospital · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Autism Spectrum Disorder with a site in China — 37 open to participants now, 38 under way, none of them phase 3. Autism Spectrum Disorder · China.
Among the 86 studies in Autism Spectrum Disorder with a site in China, this one is the 43rd largest by planned enrollment of the 63 interventional ones that give a count, is one of 19 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 17 of the 37 other live ones, and was the 64th registered.
1,728 studies on the registry are indexed under Autism Spectrum Disorder; 501 are open to participants now.
Browse Autism Spectrum Disorder studies →37 of the 86 studies in Autism Spectrum Disorder with a site in China are open now. Recruiting first, the newest first:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 4–10
Sun Fei · Sites in China
Ages 2–12
Shenzhen Children's Hospital · Sites in China
Ages 3–16
Peking University · Sites in China
Ages 3–6
Chen QiYi · Sites in China
Ages 3+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.
This study: 3 Years to 7 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 1
First in 2014; this study’s year is marked. 19 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 51 across 1,371 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 96 across the 63 interventional studies, 130 across the 23 observational. Of the 38 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 86 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dongfang People's Hospital as lead sponsor.
Dongfang People's Hospital has 1 study filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
14 of the studies in Autism Spectrum Disorder with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07532395Peking UniversityFMS-CrossFit Training Program (FCTP) to Improve School Readiness in Preschool Children With Autism Spectrum Disorder | 2026-11-24 |
| NCT07509879Qilu Hospital of Shandong UniversityResearch on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder | 2026-12-01 |
| NCT05901558Children's Hospital of Fudan UniversityStrategies for Toddler ASD With Remote-therapy (STAR) Model for ASD | 2026-12-30 |
| NCT07381374Shenzhen Children's HospitalFecal Microbiota Transplantation in Children With ASD | 2026-12-31 |
| NCT06950437Beijing Changping Tianhe Research Institute of Brain SciencepBFS Guided aiTBS Over Language Network for ASD Child | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 86 studies in Autism Spectrum Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical study aims to evaluate whether a nasal spray containing exosomes derived from human umbilical cord mesenchymal stem cells (hUC-MSC-EXOs) can safely and effectively improve core symptoms in children aged 3-7 years with autism spectrum disorder (ASD). It is a 24-week, non-randomized, controlled, open-label trial. Sixty pediatric patients with ASD will be non-randomly assigned at a 1:2 ratio to two groups: a no-intervention control group and an active exosome nasal spray treatment group. The treatment group will receive the nasal spray every other day, totaling 10 administrations throughout the study. The no-intervention control group will receive no experimental treatment but will undergo the same assessments and safety checks with the treatment group. This design aims to monitor the safety and efficacy of the hUC-MSC-EXOs nasal spray.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: hUC-MSC-Exos Nasal Spray
The total therapeutic dosage is set at 400 billion hUC-MSC-EXOs particles. Each nasal administration delivers 40 billion particles, with a total of 10 administrations completing the full course. The treatment is administered on an alternate-day schedule.
Number of Participants with Treatment-Related Adverse Events
The incidence of treatment-related adverse events will be assessed and graded according to the Common Terminology Criteria for Adverse Events version 5.0. The number of participants experiencing any treatment-related adverse event will be recorded and reported.
Time frame: Week 2, Week 6, Week 24
Childhood Autism Rating Scale, Second Edition (CARS-2) Score
Scale Description: The CARS-2 is a 15-item behavior rating scale used to diagnose and assess the severity of ASD. Range of Scores: 15 to 60. Interpretation: A higher score indicates a worse outcome.
Time frame: Week 6, Week 24
Autism Behavior Checklist (ABC)
Scale Description: The ABC is a 57-item checklist used to screen for and assess behaviors associated with ASD. Range of Scores: 0 to 158. Interpretation: A higher score indicates a worse outcome.
Time frame: Week 6, Week 24
Serum Level of Tumor Necrosis Factor-Alpha (TNF-α)
Serum concentration of the inflammatory cytokine TNF-α. The unit of measure is pg/mL.
Time frame: Week 6, Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.
Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 16, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, last on Oct 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.